Bone Biologics Corp
BBLGHealthcare·Biotechnology·USA·Nano·NASD·Nov 11 • 3:59 PM ET
0.3500+0.0088 (2.58%)
2026-11-12 02:30 CET
Market cap
1.19 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-2.89 USD m
Free cash flow, TTM
-2.63 USD m
EPS diluted, TTM
-1.61
P/E
-
Price
BBLG against its 20, 50 and 200-day averages2050200earnings
85.4% under the 52-week high of 2.39 on 23 Dec 2025. 52-week low 0.32 on 6 Nov 2026. Last 15 sessions, 33.3% high to low
Volume 0.04× normal · the line is the 50-bar volume average
Profile
BBLG52-week range, 2% of the way up
0.312.39
Bone Biologics Corp. operates as a medical device company. It engages in the research and development of bone regeneration in spinal fusion. The firm's core product is NELL-1, which is an osteostimulative recombinant protein that provides target specific control over bone regeneration. Its platform technology has application in delivering improved outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. The company was founded by Eric Kang Ting, Chia Soo and Benjamin Wu in 2004 and is headquartered in Burlington, MA.
| Employees | 2 |
|---|---|
| IPO | Mar 31, 2016 |
| Beta | 0.90 |
| ATR, 14d | 0.03 |
| Rel volume | 0.04 |
| Short float | 0.52% |
| Insider own | 0.02% |
| Inst own | 0.77% |
Snapshot
6 groupsValuation
| Index | - |
|---|---|
| Market Cap | 1.19M |
| Enterprise Value | -2.84M |
| Income | -2.89M |
| Sales | 0.00M |
| Book/sh | 2.17 |
| Cash/sh | 1.19 |
| Dividend Est. | - |
| Dividend TTM | - |
| Dividend Ex-Date | - |
| Dividend Gr. 3/5Y | - - |
| Payout | - |
| Employees | 2 |
| IPO | Mar 31, 2016 |
Ratios
| P/E | - |
|---|---|
| Forward P/E | - |
| PEG | - |
| P/S | - |
| P/B | 0.16 |
| P/C | 0.30 |
| P/FCF | - |
| EV/EBITDA | - |
| EV/Sales | - |
| Quick Ratio | 8.67 |
| Current Ratio | 8.67 |
| Debt/Eq | 0.00 |
| LT Debt/Eq | 0.00 |
| Option/Short | No / Yes |
Earnings
| EPS (ttm) | -1.61 |
|---|---|
| EPS next Y | -0.59 |
| EPS next Q | -0.17 |
| EPS this Y | 55.47% |
| EPS next Y | 50.00% |
| EPS next 5Y | - |
| EPS past 3/5Y | 75.82% 68.85% |
| Sales past 3/5Y | - - |
| EPS Y/Y TTM | 92.16% |
| Sales Y/Y TTM | - |
| EPS Q/Q | 67.57% |
| Sales Q/Q | - |
| Earnings | Sep 02 |
| EPS/Sales Surpr. | 0.00% - |
Ownership
| Insider Own | 0.02% |
|---|---|
| Insider Trans | 0.00% |
| Inst Own | 0.77% |
| Inst Trans | 4.13% |
| ROA | -50.55% |
| ROE | -54.96% |
| ROIC | -73.66% |
| Gross Margin | - |
| Oper. Margin | - |
| Profit Margin | - |
| SMA20 | -6.67% |
| SMA50 | -22.64% |
| SMA200 | -65.21% |
| Trades | - |
Technical
| Shs Outstand | 3.39M |
|---|---|
| Shs Float | 3.39M |
| Short Float | 0.52% |
| Short Ratio | 0.05 |
| Short Interest | 0.02M |
| 52W High | 2.39 -85.36% |
| 52W Low | 0.31 11.11% |
| Volatility | 12.06% 8.51% |
| ATR (14) | 0.03 |
| RSI (14) | 34.81 |
| Beta | 0.90 |
| Rel Volume | 0.04 |
| Avg Volume | 375.99K |
| Volume | 15,763 |
Performance
| Perf Week | 0.84% |
|---|---|
| Perf Month | -18.60% |
| Perf Quarter | -48.09% |
| Perf Half Y | -73.07% |
| Perf YTD | -75.86% |
| Perf Year | -79.77% |
| Perf 3Y | -98.56% |
| Perf 5Y | -99.99% |
| Perf 10Y | -100.00% |
| Recom | - |
| Target Price | 12.20 |
| Prev Close | 0.34 |
| Price | 0.35 |
| Change % | 2.58% |
Peers
Mkt cap| Ticker | Company | Mkt cap |
|---|---|---|
| BRTX | BioRestorative Therapies Inc | 2.15M |
| CLGN | CollPlant Biotechnologies Ltd | 7.48M |
| FBLG | FibroBiologics Inc | 6.63M |
| MDXG | Mimedx Group Inc | 484.47M |
| BSEM | BioStem Technologies Inc | 27.45M |
| CELZ | Creative Medical Technology Holdings Inc | 4.79M |
| VCEL | Vericel Corp | 3.03B |
| HUMA | Humacyte Inc | 164.37M |
| LCTX | Lineage Cell Therapeutics Inc | 280.72M |
| PLUR | Pluri Inc | 15.13M |
News
latest 14 of 148- Bone Biologics Expands Trial Sites (GlobeNewswire)
- Bone Biologics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference (GlobeNewswire)
- Bone Biologics Extends rhNELL-1 Validated Shelf Life to 32 Months as NB1 Study Advances (InvestorsHub) -27.60%
- Bone Biologics Achieves 32-Month Validated Shelf Life for rhNELL-1 (GlobeNewswire)
- Bone Biologics Issues Mid-Year Shareholder Update Highlighting Progress Across 2026 Priorities (GlobeNewswire)
- Bone Biologics Announces up to $9.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules (GlobeNewswire) -8.84%
- Bone Biologics Achieves 29-Month Validated Shelf Life for rhNELL-1 (GlobeNewswire)
- Bone Biologics Highlights 2025 Key Operational, Scientific, and Corporate Milestones and Provides 2026 Outlook (GlobeNewswire)
- Bone Biologics Improves Extension of rhNELL-1 Product Shelf Life to 24 Months (GlobeNewswire)
- BC-Most Active Stocks (Associated Press Finance) +37.68%
- Bone Biologics CEO Issues Letter to Stockholders Highlighting Company Update and Outlook (Business Wire)
- Bone Biologics to Participate in the H.C. Wainwright Global Investment Conference (Business Wire)
- Bone Biologics Announces Closing of $5.0 Million Public Offering (Business Wire) -12.01% -8.68%
- Bone Biologics Announces Pricing of $5.0 Million Public Offering (Business Wire) +10.10%
Quarterly earnings
actual against estimate| Period | Reported | EPS act | EPS est | EPS rep | Sales act | Sales est | Analysts |
|---|---|---|---|---|---|---|---|
| 2026Q2 | 2026-09-02 | -0.430 | -0.430 | - | 0.00 | 0.00 | 1 |
| 2026Q1 | 2026-06-03 | -0.430 | -0.430 | - | 0.00 | 0.00 | 1 |
| 2025Q4 | 2026-02-25 | -0.580 | -0.340 | -0.381 | 0.00 | 0.00 | 1 |
| 2025Q3 | 2025-12-03 | -0.370 | -0.370 | -0.371 | 0.00 | 0.00 | 1 |
| 2025Q2 | 2025-09-03 | -1.330 | -0.580 | -1.328 | 0.00 | 0.00 | 1 |
| 2025Q1 | 2025-05-28 | -0.320 | - | -1.917 | 0.00 | - | - |
| 2024Q2 | 2024-08-28 | -4.020 | -4.020 | -4.025 | 0.00 | 0.00 | 1 |
| 2024Q1 | 2024-05-29 | -7.860 | -7.860 | -7.861 | 0.00 | 0.00 | 1 |
| 2023Q4 | 2024-02-28 | -35.340 | -282.72 | -17.407 | 0.00 | 0.00 | 1 |
| 2023Q3 | 2023-11-29 | -29.280 | -29.280 | -29.399 | 0.00 | 0.00 | 1 |
| 2023Q2 | 2023-08-30 | -81.120 | -81.120 | -81.109 | 0.00 | 0.00 | 1 |
| 2023Q1 | 2023-07-29 | -11.040 | - | -331.5 | 0.00 | - | 2 |
| 2022Q4 | 2023-04-10 | 0.960 | - | 84.082 | 0.00 | - | 1 |
| 2022Q3 | 2023-02-19 | -5.760 | - | -169.63 | 0.00 | - | 2 |
| 2022Q2 | 2022-11-28 | -2.400 | - | -65.290 | 0.00 | - | 1 |
| 2022Q1 | 2022-08-20 | -3.360 | - | -95.918 | 0.00 | - | 1 |
Annual earnings
| Period | EPS act | EPS est | EPS rep | Sales act | Sales est |
|---|---|---|---|---|---|
| 2021FY | -1,613 | -950.4 | -510.67 | 0.00 | 0.00 |
| 2022FY | -96.720 | -763.2 | -187.16 | 0.00 | 0.00 |
| 2023FY | -204.06 | -204.06 | -204.05 | 0.00 | 0.00 |
| 2024FY | - | -19.020 | -28.967 | - | 0.00 |
| 2025FY | -2.650 | -2.360 | - | 0.00 | 0.00 |
| 2026FY | - | -1.180 | - | - | 0.00 |
| 2027FY | - | -0.590 | - | - | 0.00 |
Estimate revisions
last 14 periods| Period | Type | Date | Estimates | Up | Down | Mean | Low | High |
|---|---|---|---|---|---|---|---|---|
| 2026Q3 | S | 2026-09-02 | 1 | 0 | 0 | 0.00 | 0.00 | 0.00 |
| 2026Q3 | S | 2026-06-03 | 1 | 0 | 0 | 0.00 | 0.00 | 0.00 |
| 2026Q3 | S | 2026-03-02 | 1 | 0 | 0 | 0.00 | 0.00 | 0.00 |
| 2026Q3 | E | 2026-10-26 | 1 | 1 | 0 | -0.17 | -0.17 | -0.17 |
| 2026Q3 | E | 2026-09-02 | 1 | 0 | 1 | -0.19 | -0.19 | -0.19 |
| 2026Q3 | E | 2026-08-14 | 1 | 0 | 1 | -0.19 | -0.19 | -0.19 |
| 2026Q3 | E | 2026-07-07 | 1 | 1 | 0 | -0.18 | -0.18 | -0.18 |
| 2026Q3 | E | 2026-06-03 | 1 | 1 | 0 | -0.36 | -0.36 | -0.36 |
| 2026Q3 | E | 2026-05-14 | 1 | 1 | 0 | -0.36 | -0.36 | -0.36 |
| 2026Q3 | E | 2026-03-02 | 1 | 0 | 0 | -0.46 | -0.46 | -0.46 |
| 2026Q2 | S | 2026-06-03 | 1 | 0 | 0 | 0.00 | 0.00 | 0.00 |
| 2026Q2 | S | 2026-03-02 | 1 | 0 | 0 | 0.00 | 0.00 | 0.00 |
| 2026Q2 | E | 2026-08-14 | 1 | 0 | 1 | -0.43 | -0.43 | -0.43 |
| 2026Q2 | E | 2026-07-28 | 1 | 0 | 0 | -0.39 | -0.39 | -0.39 |
Estimate history
| EPS, annual | -6480 | -3173.58 | -1691.1 | -902.52 | -510.667 | -187.157 | -204.047 | -28.967 | -2.646 | -1.6101 |
|---|---|---|---|---|---|---|---|---|---|---|
| Period | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
| EPS, quarterly | -4.025 | -14.213 | -3.091 | -1.917 | -1.328 | -0.371 | -0.381 | -0.427 | -0.431 | |
| Period | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | |
| Sales, annual | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Period | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
| Sales, quarterly | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Period | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | |
| Shares, annual | 0.001 | 0.007 | 0.009 | 0.009 | 0.007 | 0.011 | 0.089 | 0.492 | 1.795 | 1.81 |
| Period | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | MRQ |
| Shares, quarterly | 0.219 | 0.349 | 0.492 | 0.545 | 1.685 | 1.795 | 1.795 | 1.795 | 1.81 | |
| Period | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 |
Income statement, annual
| Metric | TTM | 2025FY | 2024FY | 2023FY | 2022FY | 2021FY | 2020FY | 2019FY | 2018FY |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Goods Sold Incl. D&A | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 5E-05 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -5E-05 | -0.00 |
| Selling, General and Administrative Excl. Other | 3.06 | 3.23 | 4.22 | 9.43 | 3.67 | 1.10 | 0.83 | 2.45 | 2.79 |
| Research and Development | 0.90 | 1.06 | 2.13 | 6.91 | 1.58 | 0.08 | 0.34 | 1.10 | 0.10 |
| Other Operating Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -3.06 | -3.23 | -4.22 | -9.43 | -3.67 | -1.10 | -0.83 | -2.45 | -2.79 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.73 | 0.81 | 1.00 | 0.98 | 1.23 |
| Unusual Expense | -0.00 | -0.00 | -0.05 | -0.48 | -2.91 | 0.00 | 0.00 | 0.00 | 0.41 |
| Net Income Before Taxes | -2.89 | -3.11 | -4.11 | -8.95 | -1.48 | -1.61 | -1.82 | -3.42 | -4.43 |
| Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Consolidated Net Income | -2.89 | -3.11 | -4.11 | -8.95 | -1.48 | -1.61 | -1.82 | -3.42 | -4.43 |
| Net Income From Continuing Operations | -2.89 | -3.11 | -4.11 | -8.95 | -1.48 | -1.61 | -1.82 | -3.42 | -4.43 |
| Net Income | -2.89 | -3.11 | -7.32 | -8.95 | -1.48 | -1.61 | -1.82 | -3.42 | -4.43 |
| EPS (Recurring) | -1.61 | -2.65 | -29.11 | -211.67 | -444.14 | -510.67 | -902.53 | -1,691.11 | -2,968.86 |
| EPS (Basic, Before Extraordinaries) | -1.61 | -2.65 | -28.97 | -204.05 | -187.16 | -510.67 | -902.52 | -1,691.10 | -3,173.58 |
| EPS (Diluted) | -1.61 | -2.65 | -28.97 | -204.05 | -187.16 | -510.67 | -902.52 | -1,691.10 | -3,173.58 |
| EBITDA | -3.06 | -3.23 | -4.22 | -9.43 | -3.67 | -1.10 | -0.83 | -2.45 | -2.79 |
| Non-Operating Income (Expense) | 0.17 | 0.12 | 0.06 | 0.00 | 0.00 | 0.30 | 0.00 | 0.00 | 0.00 |
| Other After Tax Adjustments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock Option Compensation Expense | 0.16 | 0.26 | 0.19 | 0.12 | 0.21 | 0.15 | 0.00 | 0.04 | 0.41 |
| Shares Outstanding | 1.81 | 1.80 | 0.49 | 0.09 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| Market Capitalization | 1.19 | 1.16 | 2.78 | 1.77 | 2.17 | 36.43 | 230.12 | 260.80 | 397.00 |
Income statement, quarterly
| Metric | 2026Q2 | 2026Q1 | 2025Q4 | 2025Q3 | 2025Q2 | 2025Q1 | 2024Q4 | 2024Q3 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Goods Sold Incl. D&A | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling, General and Administrative Excl. Other | 0.81 | 0.81 | 0.73 | 0.72 | 0.75 | 1.04 | 1.55 | 0.95 |
| Research and Development | 0.31 | 0.14 | 0.26 | 0.19 | 0.19 | 0.42 | 1.10 | 0.43 |
| Other Operating Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -0.81 | -0.81 | -0.73 | -0.72 | -0.75 | -1.04 | -1.55 | -0.95 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Unusual Expense | 0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.01 | 0.01 |
| Net Income Before Taxes | -0.77 | -0.77 | -0.68 | -0.67 | -0.74 | -1.02 | -1.52 | -0.94 |
| Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Consolidated Net Income | -0.77 | -0.77 | -0.68 | -0.67 | -0.74 | -1.02 | -1.52 | -0.94 |
| Net Income From Continuing Operations | -0.77 | -0.77 | -0.68 | -0.67 | -0.74 | -1.02 | -1.52 | -0.94 |
| Net Income | -0.77 | -0.77 | -0.68 | -0.67 | -0.74 | -1.02 | -1.52 | -4.15 |
| EPS (Recurring) | -0.43 | -0.43 | -0.38 | -0.37 | -1.33 | -1.92 | -3.11 | -14.19 |
| EPS (Basic, Before Extraordinaries) | -0.43 | -0.43 | -0.38 | -0.37 | -1.33 | -1.92 | -3.09 | -14.21 |
| EPS (Diluted) | -0.43 | -0.43 | -0.38 | -0.37 | -1.33 | -1.92 | -3.09 | -14.21 |
| EBITDA | -0.81 | -0.81 | -0.73 | -0.72 | -0.75 | -1.04 | -1.55 | -0.95 |
| Non-Operating Income (Expense) | 0.03 | 0.04 | 0.05 | 0.05 | 0.01 | 0.02 | 0.02 | 0.02 |
| Other After Tax Adjustments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock Option Compensation Expense | 0.01 | 0.02 | 0.05 | 0.09 | 0.07 | 0.05 | 0.10 | 0.02 |
| Shares Outstanding | 1.81 | 1.80 | 1.80 | 1.80 | 1.69 | 0.55 | 0.49 | 0.35 |
| Market Capitalization | 1.19 | 1.97 | 2.60 | 5.01 | 2.20 | 2.62 | 2.78 | 4.47 |
Balance sheet, annual
| Metric | 2025FY | 2024FY | 2023FY | 2022FY | 2021FY | 2020FY | 2019FY | 2018FY | 2017FY |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Short Term Investments | 5.33 | 3.33 | 3.03 | 7.54 | 6.68 | 0.00 | 0.02 | 0.96 | 0.69 |
| Short Term Receivables | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Assets | 0.45 | 0.54 | 0.71 | 0.96 | 0.00 | 0.00 | 0.01 | 0.09 | 0.11 |
| Total Current Assets | 5.80 | 3.86 | 3.74 | 8.50 | 6.68 | 0.00 | 0.03 | 1.04 | 0.80 |
| Net Property, Plant & Equipment | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 5E-05 | 0.00 |
| Total Investments and Advances | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Intangible Assets | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Assets | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Assets | 5.80 | 3.86 | 3.74 | 8.50 | 6.68 | 0.00 | 0.03 | 1.04 | 0.80 |
| Short Term Debt Incl. Current Port. of LT Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 11.72 | 0.00 | 9.00 | 0.00 |
| Accounts Payable | 0.42 | 0.37 | 0.36 | 0.89 | 0.10 | 0.47 | 0.04 | 0.13 | 0.22 |
| Other Current Liabilities | 0.00 | 0.00 | 0.47 | 1.66 | 0.00 | 1.50 | 0.54 | 0.51 | 0.74 |
| Total Current Liabilities | 0.42 | 0.38 | 0.83 | 2.55 | 0.10 | 13.69 | 0.58 | 9.64 | 0.96 |
| Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 11.32 | 0.00 | 8.23 |
| Provision for Risks Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Liabilities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 0.42 | 0.38 | 0.83 | 2.55 | 0.10 | 13.69 | 11.90 | 9.64 | 9.19 |
| Non-Equity Reserves | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Stock - Carrying Value | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Equity | 5.38 | 3.48 | 2.91 | 5.95 | 6.58 | -13.69 | -11.87 | -8.60 | -8.40 |
| Total Shareholders Equity | 5.38 | 3.48 | 2.91 | 5.95 | 6.58 | -13.69 | -11.87 | -8.60 | -8.40 |
| Accumulated Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Equity | 5.38 | 3.48 | 2.91 | 5.95 | 6.58 | -13.69 | -11.87 | -8.60 | -8.40 |
| Total Liabilities & Stockholders Equity | 5.80 | 3.86 | 3.74 | 8.50 | 6.68 | 0.00 | 0.03 | 1.04 | 0.80 |
| Book Value Per Share | 3.00 | 7.08 | 32.64 | 559.67 | 914.80 | -1,606.52 | -1,392.43 | -1,170.31 | -6,983.46 |
| Tangible Book Value Per Share | 3.00 | 7.08 | 32.64 | 559.67 | 914.80 | -1,606.52 | -1,392.43 | -1,170.31 | -6,983.46 |
| Full-Time Employees | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 3 | 3 |
| Price to Book Ratio | 0.16 | 0.80 | 0.47 | 0.49 | 5.54 | -16.81 | -21.98 | -46.17 | -0.81 |
| Return on Assets | -64.38 | -108.23 | -146.30 | -19.57 | -48.26 | -11,838.26 | -639.23 | -482.52 | -797.35 |
| Return on Equity | -70.17 | -128.71 | -202.15 | -23.71 | - | - | - | - | - |
| Return on Invested Capital | -57.81 | -118.05 | -307.90 | -24.96 | -24.50 | - | - | - | - |
| Quick Ratio | 13.85 | 10.22 | 4.50 | 3.33 | 66.81 | 0.00 | 0.05 | 0.11 | 0.83 |
| Current Ratio | 13.85 | 10.22 | 4.50 | 3.33 | 66.81 | 0.00 | 0.05 | 0.11 | 0.83 |
Cash flow, annual
| Metric | TTM | 2025FY | 2024FY | 2023FY | 2022FY | 2021FY | 2020FY | 2019FY | 2018FY |
|---|---|---|---|---|---|---|---|---|---|
| Net Income | -2.89 | -3.11 | -4.11 | -8.95 | -1.48 | -1.61 | -1.82 | -3.42 | -4.43 |
| Depreciation | - | - | - | - | - | - | 0.00 | 5E-05 | 0.00 |
| Other Funds (Non Cash) | 0.16 | 0.25 | 0.14 | -0.74 | -1.91 | 0.70 | 1.00 | 0.03 | 0.18 |
| Funds from Operations | -2.73 | -2.86 | -3.97 | -9.69 | -3.40 | -0.91 | -0.83 | -3.40 | -4.25 |
| Extraordinary Item | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Changes in Working Capital | 0.10 | 0.17 | -0.15 | 0.13 | -0.17 | -0.32 | 0.40 | 0.14 | 0.15 |
| Cash from Operating Activities | -2.63 | -2.69 | -4.12 | -9.56 | -3.57 | -1.23 | -0.43 | -3.25 | -4.10 |
| Capital Expenditures | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Assets From Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Fixed Assets and Businesses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchase or Sale of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchase of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale Or Maturity of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Sources | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Dividends Paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Capital Stock | 0.02 | 4.70 | 4.42 | 5.04 | 4.43 | 6.86 | 0.00 | 0.00 | 4.37 |
| Repurchase of Common Pref Stock | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Common Pref Stock | 0.02 | 4.70 | 4.42 | 5.04 | 4.43 | 6.86 | 0.00 | 0.00 | 4.37 |
| Proceedsfrom Stock Options | 0.02 | 0.35 | 1.11 | 5.04 | 4.43 | 6.86 | 0.00 | 0.00 | 4.37 |
| Issuance or Reduction of Debt, Net | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.05 | 0.40 | 2.32 | 0.00 |
| Change in Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.32 | 0.00 |
| Issuance of Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.32 | 0.60 |
| Reduction of Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.60 |
| Net Financing Active Other Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Activities Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Financing Activities | 0.02 | 4.70 | 4.42 | 5.04 | 4.43 | 7.90 | 0.40 | 2.32 | 4.37 |
| Net Change in Cash | -2.61 | 2.01 | 0.30 | -4.51 | 0.86 | 6.68 | -0.02 | -0.93 | 0.27 |
| Free Cash Flow | -2.63 | -2.69 | -4.12 | -9.56 | -3.57 | -1.23 | -0.43 | -3.25 | -4.10 |
| Preferred Dividends (Cash Flow) | - | 0.00 | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Deferred Taxes & Investment Tax Credit | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Balance sheet, quarterly
| Metric | 2026Q2 | 2026Q1 | 2025Q4 | 2025Q3 | 2025Q2 | 2025Q1 |
|---|---|---|---|---|---|---|
| Cash & Short Term Investments | 4.03 | 4.53 | 5.33 | 6.05 | 6.64 | 2.75 |
| Short Term Receivables | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Assets | 0.40 | 0.44 | 0.45 | 0.30 | 0.36 | 0.42 |
| Total Current Assets | 4.44 | 4.98 | 5.80 | 6.35 | 7.00 | 3.16 |
| Net Property, Plant & Equipment | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Investments and Advances | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Intangible Assets | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Assets | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Assets | 4.44 | 4.98 | 5.80 | 6.35 | 7.00 | 3.16 |
| Short Term Debt Incl. Current Port. of LT Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Accounts Payable | 0.51 | 0.31 | 0.42 | 0.33 | 0.40 | 0.25 |
| Other Current Liabilities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Current Liabilities | 0.51 | 0.31 | 0.42 | 0.33 | 0.41 | 0.25 |
| Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Provision for Risks Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Liabilities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 0.51 | 0.31 | 0.42 | 0.33 | 0.41 | 0.25 |
| Non-Equity Reserves | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Stock - Carrying Value | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Equity | 3.92 | 4.67 | 5.38 | 6.02 | 6.60 | 2.91 |
| Total Shareholders Equity | 3.92 | 4.67 | 5.38 | 6.02 | 6.60 | 2.91 |
| Accumulated Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Equity | 3.92 | 4.67 | 5.38 | 6.02 | 6.60 | 2.91 |
| Total Liabilities & Stockholders Equity | 4.44 | 4.98 | 5.80 | 6.35 | 7.00 | 3.16 |
| Book Value Per Share | 2.17 | 2.60 | 3.00 | 3.35 | 3.91 | 5.34 |
| Tangible Book Value Per Share | 2.17 | 2.60 | 3.00 | 3.35 | 3.91 | 5.34 |
| Full-Time Employees | - | - | 2 | - | - | - |
| Price to Book Ratio | 0.16 | 0.37 | 0.43 | 0.71 | 0.75 | 0.90 |
| Return on Assets | -50.55 | -70.21 | -64.38 | -75.76 | -82.79 | -121.79 |
| Return on Equity | -54.96 | -75.40 | -70.17 | -80.46 | -88.80 | -129.48 |
| Return on Invested Capital | -19.71 | -16.40 | -12.73 | -11.08 | -11.23 | -34.94 |
| Quick Ratio | 8.67 | 16.09 | 13.85 | 19.00 | 17.24 | 12.59 |
| Current Ratio | 8.67 | 16.09 | 13.85 | 19.00 | 17.24 | 12.59 |
Cash flow, quarterly
| Metric | 2026Q2 | 2026Q1 | 2025Q4 | 2025Q3 | 2025Q2 | 2025Q1 |
|---|---|---|---|---|---|---|
| Net Income | -0.77 | -0.77 | -0.68 | -0.67 | -0.74 | -1.02 |
| Other Funds (Non Cash) | 0.01 | 0.02 | 0.05 | 0.09 | 0.07 | 0.05 |
| Funds from Operations | -0.77 | -0.74 | -0.64 | -0.58 | -0.67 | -0.97 |
| Extraordinary Item | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Changes in Working Capital | 0.25 | -0.06 | -0.08 | -0.01 | 0.21 | 0.04 |
| Cash from Operating Activities | -0.52 | -0.80 | -0.71 | -0.59 | -0.46 | -0.93 |
| Capital Expenditures | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Assets From Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Fixed Assets and Businesses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchase or Sale of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchase of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale Or Maturity of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Sources | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Dividends Paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Dividends (Cash Flow) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Capital Stock | 0.02 | 0.00 | 0.00 | 0.00 | 4.35 | 0.35 |
| Repurchase of Common Pref Stock | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Common Pref Stock | 0.02 | 0.00 | 0.00 | 0.00 | 4.35 | 0.35 |
| Proceedsfrom Stock Options | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.35 |
| Issuance or Reduction of Debt, Net | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Issuance of Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Reduction of Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Financing Active Other Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Activities Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Financing Activities | 0.02 | 0.00 | 0.00 | 0.00 | 4.35 | 0.35 |
| Net Change in Cash | -0.50 | -0.80 | -0.71 | -0.59 | 3.89 | -0.58 |
| Free Cash Flow | -0.52 | -0.80 | -0.71 | -0.59 | -0.46 | -0.93 |
Revenue breakdown
| Revenue split | - |
|---|
Short interest
shares short against float, oldest to newest| Settlement | Of float | Shares short | Float | Avg volume |
|---|---|---|---|---|
| 2026-10-30 | 0.52% | 0.0M | 3.4M | 375.73K |
| 2026-10-15 | 0.83% | 0.0M | 2.8M | 374.84K |
| 2026-09-30 | 1.79% | 0.0M | 2.8M | 384.83K |
| 2026-09-15 | 1.30% | 0.0M | 2.8M | 334.87K |
| 2026-08-31 | 1.34% | 0.0M | 2.8M | 327.47K |
| 2026-08-14 | 5.67% | 0.2M | 2.8M | 320.17K |
| 2026-07-31 | 1.16% | 0.0M | 1.8M | 60.88K |
| 2026-07-15 | 1.47% | 0.0M | 1.8M | 58.11K |
| 2026-06-30 | 3.76% | 0.1M | 1.8M | 47.74K |
| 2026-06-15 | 0.27% | 0.0M | 1.8M | 14.76K |
| 2026-05-29 | 0.26% | 0.0M | 1.8M | 15.26K |
| 2026-05-15 | 0.16% | 0.0M | 1.8M | 14.82K |
| 2026-04-30 | 0.58% | 0.0M | 1.8M | 16.73K |
| 2026-04-15 | 0.40% | 0.0M | 1.8M | 20.88K |
| 2026-03-31 | 0.80% | 0.0M | 1.8M | 25.69K |
| 2026-03-13 | 1.46% | 0.0M | 1.8M | 304.24K |
| 2026-02-27 | 1.70% | 0.0M | 1.8M | 300.79K |
| 2026-02-13 | 2.33% | 0.0M | 1.8M | 305.55K |
| 2026-01-30 | 2.53% | 0.0M | 1.8M | 306.66K |
| 2026-01-15 | 2.28% | 0.0M | 1.8M | 301.75K |
Option chain
expiry 2026-11-11| Type | Strike | Bid | Ask | Last | IV | Open int | Volume | Delta | Theta | Vega |
|---|---|---|---|---|---|---|---|---|---|---|
| No option chain for this symbol. | ||||||||||
Latest SEC filings
30| Filed | Form | Description | Period | Link |
|---|---|---|---|---|
| 2026-11-10 | SCHEDULE 13G/A | SEC | ||
| 2026-10-26 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) | 2026-09-30 | SEC |
| 2026-10-13 | 25-NSE | SEC | ||
| 2026-09-30 | 4 | Statement of changes in beneficial ownership of securities | 2026-09-28 | SEC |
| 2026-09-30 | 4 | Statement of changes in beneficial ownership of securities | 2026-09-28 | SEC |
| 2026-09-30 | 4 | Statement of changes in beneficial ownership of securities | 2026-09-28 | SEC |
| 2026-09-30 | 4 | Statement of changes in beneficial ownership of securities | 2026-09-28 | SEC |
| 2026-09-29 | 8-K | Current report | 2026-09-28 | SEC |
| 2026-09-16 | 8-K | Current report | 2026-09-10 | SEC |
| 2026-08-28 | DEF 14A | Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 | 2026-08-28 | SEC |
| 2026-08-18 | PRE 14A | Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 | 2026-08-18 | SEC |
| 2026-08-14 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) | 2026-06-30 | SEC |
| 2026-07-24 | EFFECT | Effectiveness filing by commission order | SEC | |
| 2026-07-24 | 424B3 | SEC | ||
| 2026-07-23 | 8-K | Current report | 2026-07-23 | SEC |
| 2026-07-20 | DEFA14A | Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 | SEC | |
| 2026-07-17 | S-3 | Registration statement for specified transactions by certain issuers including face-amount certificate companies | SEC | |
| 2026-07-16 | 8-K | Current report | 2026-07-15 | SEC |
| 2026-07-09 | 8-K | Current report | 2026-07-07 | SEC |
| 2026-07-02 | ARS | Annual report to security holders. | 2025-12-31 | SEC |
| 2026-07-02 | DEFA14A | Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 | SEC | |
| 2026-07-02 | DEF 14A | Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 | 2026-07-02 | SEC |
| 2026-05-14 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) | 2026-03-31 | SEC |
| 2026-03-13 | 8-K | Current report | 2026-03-13 | SEC |
| 2026-03-13 | 424B5 | SEC | ||
| 2026-03-02 | 10-K | Annual report pursuant to Section 13 or 15(d) | 2025-12-31 | SEC |
| 2026-01-21 | 4 | Statement of changes in beneficial ownership of securities | 2026-01-08 | SEC |
| 2026-01-21 | 4 | Statement of changes in beneficial ownership of securities | 2026-01-08 | SEC |
| 2026-01-08 | 8-K | Current report | 2026-01-08 | SEC |
| 2025-11-14 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) | 2025-09-30 | SEC |
Insider activity by month
| Month | Bought | Buys | Sold | Sells |
|---|---|---|---|---|
| 2026-11 | 0 | 0 | 0 | 0 |
| 2026-10 | 0 | 0 | 0 | 0 |
| 2026-09 | 0 | 0 | 0 | 0 |
| 2026-08 | 0 | 0 | 0 | 0 |
| 2026-07 | 0 | 0 | 0 | 0 |
| 2026-06 | 0 | 0 | 0 | 0 |
| 2026-05 | 0 | 0 | 0 | 0 |
| 2026-04 | 0 | 0 | 0 | 0 |
| 2026-03 | 0 | 0 | 0 | 0 |
| 2026-02 | 0 | 0 | 0 | 0 |
| 2026-01 | 0 | 0 | 0 | 0 |
| 2025-12 | 0 | 0 | 0 | 0 |
| 2025-11 | 0 | 0 | 0 | 0 |
Institutional holders
| Manager | % owned |
|---|---|
| CITADEL ADVISORS LLC | 1.33% |
| Tower Research Capital LLC | 0.11% |
| SBI Securities Co., Ltd. | 0.01% |
| Caitong International Asset Management Co., Ltd | 0.00% |
Funds
| Fund | % owned |
|---|---|
| Fidelity Extended Market Index Fund | 0.28% |
| Fidelity Total Market Index Fund | 0.02% |
OakChart. BBLG. Cached 15 minutes.
Some panels did not load: ratings, insider.